Gavin Hirst

About Gavin Hirst

Drug discovery executive leader and Medicinal Chemist with expertise spanning 5 therapeutic areas. I have a sustained record of optimizing drug-like properties using both traditional and collaborative AI approaches to deliver high-quality development candidates and IND\'s in both global pharmaceutical companies and emerging biotechnology ventures.Delivered multiple compounds into clinical development and I am co-inventor of the FDA approved drug Vabomere for the treatment of cUTI\'sI am actively seeking opportunities to serve on boards where I can contribute my experience and insights to help guide organizations toward continued success Scientific advisor to emerging biopharmaceutical companies to integrate pipeline build with platform approach. Includes contributing to the selection of therapeutic areas, indications & protein targets,Executed multiple strategic portfolio reviews and prioritizationsSpearheaded research alliances and collaborations as member of multiple joint-steering committeesDeep Structure-Based and Fragment-Based Drug Discovery (SBDD, FBDD) knowledge. I am known as being a change agent and team builder with a focus on coaching and developing colleagues to improve performance, accelerate portfolios and grow careers.Expertise in drug discovery management and leadership of Medicinal Chemistry, DMPK, Analytical Chemistry, Toxicology, Computational Chemistry, Biological Sciences, Research Informatics, Project Management and Systems EngineeringSkilled in prosecuting discovery efforts across many gene families, in particular kinases, ion channels, transferases, cytokine receptors, nuclear receptors, protein degraders, hydrolases, lactamases, GPCR’s, phosphatases, bacterial efflux pumps and peptidasesAuthored more than 100 scientific publications, presentations, book chapters, patents, and patent applications

Experience

1. Advisory Board Member

   Intelligence Ventures

   Aug 2023 — Present

   Emerging venture capital firm focused on innovation at the intersection of artificial intelligence and healthcare via early stage strategic investments in pre-seed, seed, and Series A companies in the US

Education

• University of Southampton

  Ph.D, Organic chemistry

• University of Bradford

  B.Sc, Chemistry

Skills

• Lead Change
• Chemistry
• Budget Management
• Lc-Ms
• Medicinal Chemistry
• Life Sciences
• Purification
• Drug Design
• Drug Development
• Organic Chemistry
• Adme
• Biotechnology
• Parallel Synthesis
• High Throughput Screening
• Clinical Development
• Alliance Management
• Drug Discovery
• Organic Synthesis
• Assay Development
• Research
• Pharmaceutical Industry
• Structure Based Drug Design
• Fragment Based Drug Discovery